ArticleClinical and experimental immunology2001
Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls.
Article in Clinical and experimental immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Exploring the various functions of PHD finger protein 20: beyond the unknown.Toxicological research · 2025Review
- Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials.Journal of nanobiotechnology · 2024Review
- N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.Clinical and translational medicine · 2022Article
- miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1.Oncology letters · 2020Article
- PHF20 Promotes Glioblastoma Cell Malignancies Through aFrontiers in oncology · 2020Article
- Dendritic cells transduced with glioma-expressed antigen 2 recombinant adenovirus induces specific cytotoxic lymphocyte response and anti-tumor effect in mice.Journal of inflammation (London, England) · 2020Article
- PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.Journal of molecular cell biology · 2018Article
- Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.Oncology letters · 2017Article
- Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line.Cancer cell international · 2017Article
- Article
- Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.Oncotarget · 2015Article
- Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression.International journal of clinical and experimental pathology · 2015Article
- Biomarkers of pediatric brain tumors.Frontiers in pediatrics · 2013Review
- Article
- PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65.Nature communications · 2013Article
- PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53.Nature structural & molecular biology · 2012Article
- Improving seroreactivity-based detection of glioma.Neoplasia (New York, N.Y.) · 2009Article
- Combining gene expression signatures and autoantibody profiles in human meningioma.Gene therapy · 2009Article
- Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation.PloS one · 2008Article
- Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.Cancer immunity · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma constitutes the most frequent brain tumour in man with glioblastoma as the most prevalent and malignant type. The average survival time of less than 16 months underlines the need for improvements in diagnosis and therapy. Here, we report the identification of a novel antigen termed glioma-expressed antigen 2 (GLEA2) causing a frequent immune response in glioma patients. Screening of 450 000 clones from a glioblastoma lambda zap expression library with autologous patient serum revealed a group of five serum-positive clones sharing a high sequence homology. Further sequence analysis showed a sequence homology to a hepatocellular carcinoma associated antigen 58 (HCA58). We localized the novel HCA homologous gene termed glioma-expressed antigen 2 (GLEA2) on chromosome 20 by somatic cell hybrid panel mapping. Using allogenic sera from 39 glioblastoma patients, we found an immune response against GLEA2 in 17 patients (43%). In addition, screening with allogenic sera from other glioma patients revealed GLEA2 directed antibodies in two out of five pilocytic astrocytomas and in one out of two astrocytomas. Unrelated tumour sera revealed no immune response and sera from healthy persons showed an immune response in two out of 14 cases (14%). Northern blot hybridization and RT-PCR showed ubiquitous GLEA2 gene expression in glioma and normal tissues. The novel HCA homologous gene, GLEA2, appears to induce a frequent immune response in glioma. In the light of the lack of useful glioma markers, it appears reasonable to consider GLEA2 as a potential future diagnostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.